WT1 as an immunotherapy target for thymic epithelial tumors: a novel method to activate anti-tumor immunity.
作者信息
Takahashi Nobuyuki, Zhao Chen, Rajan Arun
机构信息
Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Mediastinum. 2019 Apr;3. doi: 10.21037/med.2019.03.03. Epub 2019 Apr 8.
Abstract
摘要
相似文献
1
WT1 as an immunotherapy target for thymic epithelial tumors: a novel method to activate anti-tumor immunity.
Mediastinum. 2019 Apr;3. doi: 10.21037/med.2019.03.03. Epub 2019 Apr 8.
2
WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21.
3
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
Clin Cancer Res. 2009 Apr 15;15(8):2789-96. doi: 10.1158/1078-0432.CCR-08-2589. Epub 2009 Apr 7.
4
Immunotherapeutic targeting of Wilms' tumor protein.
Curr Opin Mol Ther. 2007 Feb;9(1):62-9.
5
Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
J Immunol. 2000 Feb 15;164(4):1873-80. doi: 10.4049/jimmunol.164.4.1873.
6
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
Oncologist. 2012;17(2):250-9. doi: 10.1634/theoncologist.2011-0240. Epub 2012 Jan 30.
7
WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Cancer Immunol Immunother. 2004 Jul;53(7):617-24. doi: 10.1007/s00262-003-0498-0. Epub 2004 Feb 7.
8
Immunotherapy in thymic epithelial tumors: an attractive dilemma.
Invest New Drugs. 2025 Feb;43(1):69-73. doi: 10.1007/s10637-024-01497-1. Epub 2025 Jan 2.
9
Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.
Cancer Immunol Immunother. 2017 Jun;66(6):787-798. doi: 10.1007/s00262-017-1984-0. Epub 2017 Mar 15.
10
WT1 Pulsed Human CD141+ Dendritic Cell Vaccine Has High Potential in Solid Tumor-Targeted Immunotherapy.
Int J Mol Sci. 2023 Jan 12;24(2):1501. doi: 10.3390/ijms24021501.
引用本文的文献
1
Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors.
Explor Target Antitumor Ther. 2024;5(3):465-476. doi: 10.37349/etat.2024.00229. Epub 2024 May 21.
2
Immunotherapy for thymoma.
J Thorac Dis. 2020 Dec;12(12):7635-7641. doi: 10.21037/jtd-2019-thym-12.
3
Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?
Mediastinum. 2019 Sep;3. doi: 10.21037/med.2019.08.02. Epub 2019 Sep 9.
本文引用的文献
1
Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
Cancer Immunol Immunother. 2019 Jan;68(1):121-130. doi: 10.1007/s00262-018-2257-2. Epub 2018 Oct 10.
2
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.
Ann Rheum Dis. 2019 Jan;78(1):150-152. doi: 10.1136/annrheumdis-2018-213777. Epub 2018 Sep 5.
3
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
J Clin Oncol. 2019 Aug 20;37(24):2162-2170. doi: 10.1200/JCO.2017.77.3184. Epub 2018 Jun 15.
4
The Integrated Genomic Landscape of Thymic Epithelial Tumors.
Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.
5
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.
Lancet Oncol. 2018 Mar;19(3):347-355. doi: 10.1016/S1470-2045(18)30062-7. Epub 2018 Jan 26.
6
WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21.
7
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oncol Res Treat. 2017;40(11):682-690. doi: 10.1159/000481353. Epub 2017 Oct 18.
8
Transient Treg depletion enhances therapeutic anti-cancer vaccination.
Immun Inflamm Dis. 2016 Nov 21;5(1):16-28. doi: 10.1002/iid3.136. eCollection 2017 Mar.
9
Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells.
Anticancer Res. 2016 Jul;36(7):3715-24.
10
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Int J Cancer. 2016 Sep 15;139(6):1391-401. doi: 10.1002/ijc.30182. Epub 2016 May 31.
Zotero 插件